08:57 AM EDT, 06/25/2024 (MT Newswires) -- WAVE Life Sciences ( WVE ) said Tuesday it has seen "positive" results from a Phase 1b/2a trial of WVE-003 to treat people with Huntington's disease by lowering mutant huntingtin protein and preserving healthy, wild-type huntingtin protein.

In the multidose portion of the trial, WVE-003 was "generally safe and well-tolerated, with no serious adverse events reported," the company said.

Wave Life Sciences ( WVE ) also said that the "strong data compel a case for accelerated approval for WVE-003."

Huntington's disease is a debilitating neurological disorder.

Shares of the biotechnology company were up over 4% in Tuesday's premarket activity.

Price: 5.45, Change: +0.24, Percent Change: +4.61